Travere Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Travere Therapeutics (TVTX) will release Q3 2026 results on Nov. 2, 2026, after market close. A webcast and dial-in will be available, with an archive accessible for 30 days. The company focuses on developing therapies for rare diseases.
Travere Therapeutics (TVTX) reported Phase 3 data showing FILSPARI reduced urinary biomarkers in IgA nephropathy patients over 110 weeks, compared to irbesartan. The results suggest potential modulation of the disease's biology, extending prior efficacy findings.
Travere Therapeutics (TVTX) presented Phase 3 PROTECT Study data showing FILSPARI (sparsentan) reduced kidney inflammation biomarkers more than irbesartan in IgA nephropathy patients. At Week 110, FILSPARI decreased sCD163 (60.1%), BAFF (64.4%), C5b-9 (50.2%), and IL-6 (45.4%) compared to irbesartan. The study involved 404 patients, with 295 analyzed for biomarkers.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning TVTX (Travere Therapeutics, Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent TVTX coverage spans financial news, corporate actions and earnings.
In the last 30 days, TVTX insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($13.1M). The most active reporter was Dube Eric M, CHIEF EXECUTIVE OFFICER, with 3 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The announcement may prompt modest positioning ahead of the earnings release.
Positive Phase 3 biomarker data may boost investor confidence in FILSPARI's efficacy for IgA nephropathy.
Positive Phase 3 biomarker results suggest stronger efficacy for FILSPARI, likely boosting investor confidence.
Large insider sell by the CEO may signal confidence concerns, prompting short-term price pressure.
Positive trial outcomes suggest stronger market demand for FILSPARI.
AlphAI scores every news story that mentions TVTX with an AI model for sentiment and relevance, and aggregates insider trades from Travere Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Travere Therapeutics (TVTX) will release Q3 2026 results on Nov. 2, 2026, after market close. A webcast and dial-in will be available, with an archive accessible for 30 days. The company focuses on developing therapies for rare diseases.
1 min readTravere Therapeutics (TVTX) reported Phase 3 data showing FILSPARI reduced urinary biomarkers in IgA nephropathy patients over 110 weeks, compared to irbesartan. The results suggest potential modulation of the disease's biology, extending prior efficacy findings.
2 min readTravere Therapeutics (TVTX) presented Phase 3 PROTECT Study data showing FILSPARI (sparsentan) reduced kidney inflammation biomarkers more than irbesartan in IgA nephropathy patients. At Week 110, FILSPARI decreased sCD163 (60.1%), BAFF (64.4%), C5b-9 (50.2%), and IL-6 (45.4%) compared to irbesartan. The study involved 404 patients, with 295 analyzed for biomarkers.
2 min readDube Eric M (CHIEF EXECUTIVE OFFICER) sold 243,735 shares of Travere Therapeutics, Inc. (TVTX) at an average of $53.82 ($52.97–$55.02, $13.12M total) across 3 trades on 2026-10-15 under a Rule 10b5-1 trading plan.
1 min readTravere Therapeutics (TVTX) will present data at ASN Kidney Week 2026. FILSPARI (sparsentan) showed 75% complete proteinuria remission in IgAN and better outcomes than irbesartan in FSGS. Key data: 75% remission, eGFR stabilization, and lower kidney failure rates.
2 min readTravere Therapeutics (TVTX) will present data on FILSPARI at ASN 2026, showing 75% remission in IgAN and slower eGFR decline in FSGS. The studies also indicate greater proteinuria reduction compared to irbesartan. According to the company, these results reinforce FILSPARI's effectiveness in these indications.
1 min readTravere Therapeutics (TVTX) received a patent extension for FILSPARI, protecting its use in focal segmental glomerulosclerosis until October 2037. The company's stock has shown mixed performance, down 9.49% over 30 days but up 51.80% year-to-date. Analysts debate its valuation, with some seeing it as 19% undervalued at $59.99, while others note its higher P/S ratio compared to peers.
2 min readHC Wainwright & Co. maintained a Buy rating on Travere Therapeutics (TRVRS) with a $67 price target, suggesting a 6.6% upside from the Sep 21 close. The firm cited strong leadership transition and confidence in product execution as key reasons for their rating.
1 min readTravere Therapeutics (TVTX) shares dropped 2.3% after-hours on news of CEO Eric Dube's planned departure in December 2026. Bradley Campbell, former Amicus Therapeutics CEO, will succeed Dube. Dube will stay as advisor until February 2027. The board praised Campbell's experience in rare disease therapies.
2 min readTravere Therapeutics, Inc. (TVTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b)(c)(d) On September 21, 2026, Travere Therapeutics, Inc. (the “Company”) and Eric Dube, Ph.D., mutually agreed to the ti
1 min read
